Cordier F, Hoorens A, Ferdinande L, Van Dorpe J, Creytens D. Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination. World J Clin Cases 2023; 11(20): 4734-4739 [PMID: 37584005 DOI: 10.12998/wjcc.v11.i20.4734]
Corresponding Author of This Article
David Creytens, MD, PhD, Department of Pathology, UZ Ghent, Corneel Heymanslaan 10 B-9000 Ghent Belgium, Ghent 9000, Belgium. david.creytens@uzgent.be
Research Domain of This Article
Pathology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 16, 2023; 11(20): 4734-4739 Published online Jul 16, 2023. doi: 10.12998/wjcc.v11.i20.4734
Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination
Fleur Cordier, Anne Hoorens, Liesbeth Ferdinande, Jo Van Dorpe, David Creytens
Fleur Cordier, Anne Hoorens, Liesbeth Ferdinande, Jo Van Dorpe, David Creytens, Department of Pathology, Ghent University Hospital, Ghent 9000, Belgium
Author contributions: Cordier F performed the writing of the paper and made the figures; Creytens D performed the study concept, design and review of the paper; Hoorens A, Ferdinande L and Van Dorpe J performed review of the paper; all authors read and approved the final paper.
Conflict-of-interest statement: The authors state that there are no conflicts of interests to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: David Creytens, MD, PhD, Department of Pathology, UZ Ghent, Corneel Heymanslaan 10 B-9000 Ghent Belgium, Ghent 9000, Belgium. david.creytens@uzgent.be
Received: February 17, 2023 Peer-review started: February 17, 2023 First decision: May 18, 2023 Revised: May 31, 2023 Accepted: June 26, 2023 Article in press: June 26, 2023 Published online: July 16, 2023 Processing time: 144 Days and 16.8 Hours
Abstract
Inflammatory myofibroblastic tumor (IMT) of the biliary tract is rare, and often difficult to diagnose or to distinguish from other tumors due to its atypical clinical presentation and nonspecific radiological features. Histologically, IMTs are (myo)fibroblastic neoplasms with a prominent inflammatory infiltrate. They are characterized by receptor tyrosine kinase gene rearrangements, most often involving an anaplastic lymphoma kinase (ALK) translocation. The final diagnosis of IMT depends on histopathology and immunohistochemical examination. In this manuscript, we provide a clinical and morphomolecular overview of IMT and the difficulties that may arise in using immunohistochemical and molecular techniques in diagnosing IMT.
Core Tip: Inflammatory myofibroblastic tumor (IMT) of the intrapancreatic biliary tract is rare and often difficult to diagnose. In this manuscript, we give a recent update of the clinicopathological features of IMT with focus on the pathological and molecular characteristics.
